STAT Plus Sanofi suffers setback as panel recommends against dengue vaccine in adults

STAT Plus: Sanofi suffers setback as panel recommends against dengue vaccine in adults

Sanofi suffered a major setback in its bid to market a controversial dengue vaccine in the United States, as an FDA advisory committee recommended against approval for adults.

More From BioPortfolio on "STAT Plus: Sanofi suffers setback as panel recommends against dengue vaccine in adults"